Difference between revisions of "Global Template"
Jump to navigation
Jump to search
| [unchecked revision] | [unchecked revision] |
| Line 16: | Line 16: | ||
==Definition / Description of Disease== | ==Definition / Description of Disease== | ||
| + | Put your text here | ||
==Synonyms / Terminology== | ==Synonyms / Terminology== | ||
| + | Put your text here | ||
==Epidemiology / Prevalence== | ==Epidemiology / Prevalence== | ||
| + | Put your text here | ||
==Clinical Features== | ==Clinical Features== | ||
| + | Put your text here | ||
==Sites of Involvement== | ==Sites of Involvement== | ||
| + | Put your text here | ||
==Morphologic Features== | ==Morphologic Features== | ||
| + | Put your text here | ||
==Immunophenotype== | ==Immunophenotype== | ||
| + | |||
| + | Put your text here or fill in the table | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 48: | Line 56: | ||
===Additional Description:=== | ===Additional Description:=== | ||
| + | |||
| + | Put your text here | ||
==Chromosomal Rearrangements (Gene Fusions)== | ==Chromosomal Rearrangements (Gene Fusions)== | ||
| + | |||
| + | Put your text here or fill in the table | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 61: | Line 73: | ||
===Additional Description:=== | ===Additional Description:=== | ||
| + | |||
| + | Put your text here | ||
==Characteristic Chromosomal Aberrations / Patterns== | ==Characteristic Chromosomal Aberrations / Patterns== | ||
| + | |||
| + | Put your text here | ||
==Genomic Gain/Loss/LOH== | ==Genomic Gain/Loss/LOH== | ||
| + | Put your text here or fill in the table | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 77: | Line 94: | ||
===Additional Description:=== | ===Additional Description:=== | ||
| + | |||
| + | Put your text here | ||
==Gene Mutations (SNV/INDEL)== | ==Gene Mutations (SNV/INDEL)== | ||
| + | |||
| + | Put your text here or fill in the table | ||
{| class="wikitable sortable" | {| class="wikitable sortable" | ||
| Line 90: | Line 111: | ||
*Other Mutations | *Other Mutations | ||
| − | *Concomitant Mutations | + | Put your text here |
| − | *Secondary Mutations | + | *Concomitant Mutations |
| + | Put your text here | ||
| + | *Secondary Mutations | ||
| + | Put your text here | ||
*Mutually Exclusive | *Mutually Exclusive | ||
| + | Put your text here | ||
==Epigenomics (Methylation)== | ==Epigenomics (Methylation)== | ||
| + | Put your text here | ||
==Genes and Main Pathways Involved== | ==Genes and Main Pathways Involved== | ||
| + | Put your text here | ||
==Diagnostic Testing Methods== | ==Diagnostic Testing Methods== | ||
| + | Put your text here | ||
==Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)== | ==Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)== | ||
| + | Put your text here | ||
==Familial Forms== | ==Familial Forms== | ||
| + | Put your text here | ||
==Other Information== | ==Other Information== | ||
| + | Put your text here | ||
==Links== | ==Links== | ||
| + | Put your links here | ||
==References== | ==References== | ||
| − | |||
| − | |||
| − | |||
=== Reference Example, BOOK === | === Reference Example, BOOK === | ||
Revision as of 14:36, 13 April 2017
Primary Author(s)
Primary authors will typically be those that initially create and complete the content of a page. If a subsequent user modifies the content and feels the effort put forth is of high enough significance to warrant listing in the authorship section, please contact the CCGA coordinators (contact information provided on the homepage). Additional global feedback or concerns are also welcome.
Cancer Category/Type
Put your text here
Cancer Sub-Classification / Subtype
Put your text here
Definition / Description of Disease
Put your text here
Synonyms / Terminology
Put your text here
Epidemiology / Prevalence
Put your text here
Clinical Features
Put your text here
Sites of Involvement
Put your text here
Morphologic Features
Put your text here
Immunophenotype
Put your text here or fill in the table
| Finding | Marker |
|---|---|
| Positive (universal) | CD1 |
| Positive (subset) | CD2 |
| Negative (universal) | CD3 |
| Negative (subset) | CD4 |
Additional Description:
Put your text here
Chromosomal Rearrangements (Gene Fusions)
Put your text here or fill in the table
| Chromosomal Rearrangement | Genes in Fusion (5’ or 3’ Segments) | Pathogenic Derivative | Prevalence |
|---|---|---|---|
| t(9;22) | BCR-ABL1 | der(22) | 5% |
| t(8;21) | RUNX1-RUNXT1 | der(8) | 5% |
Additional Description:
Put your text here
Characteristic Chromosomal Aberrations / Patterns
Put your text here
Genomic Gain/Loss/LOH
Put your text here or fill in the table
| Chromosome Number | Gain/Loss/Amp/LOH | Region |
|---|---|---|
| 8 | Gain | chr8:0-1000000 |
| 7 | Loss | chr7:0-1000000 |
Additional Description:
Put your text here
Gene Mutations (SNV/INDEL)
Put your text here or fill in the table
| Gene | Mutation | Oncogene/Tumor Suppressor/Other | Presumed Mechanism (LOF/GOF/Other; Driver/Passenger) | Prevalence (COSMIC/TCGA/Other) |
|---|---|---|---|---|
| TP53 | R273H | Tumor Suppressor | LOF | 20% |
Additional Description:
- Other Mutations
Put your text here
- Concomitant Mutations
Put your text here
- Secondary Mutations
Put your text here
- Mutually Exclusive
Put your text here
Epigenomics (Methylation)
Put your text here
Genes and Main Pathways Involved
Put your text here
Diagnostic Testing Methods
Put your text here
Clinical Significance (Diagnosis, Prognosis and Therapeutic Implications)
Put your text here
Familial Forms
Put your text here
Other Information
Put your text here
Links
Put your links here
References
Reference Example, BOOK
- Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A, Thiele J, Bloomfield CD (2008). Acute myeloid leukaemia with recurrent genetic abnormalities, in World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4thedition.Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, Editors. IARC Press: Lyon, France, p117-118.
Reference Example, Journal Article
- Li Y, Mehta PK, Nizetic D, Kaneko Y, Chan GCF, Chan LC, Squire J, Scherer SW and Hitzler JK (2001). Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nat Genet 28:220-221, PMID 11431691.